GLP-1 receptor agonists not linked to increased NAION risk in adults with optic disc drusen

Nonarteritic anterior ischemic optic neuropathy (NAION) is a sudden, painless loss of vision caused by insufficient blood flow to the optic nerve head. It is a significant cause of vision impairment, particularly in individuals with predisposing factors like optic disc drusen and underlying vascular risk factors such as type-2-diabetes and obesity. Recent observational studies have presented conflicting evidence regarding a potential association between glucagon-like peptide-1 receptor agonists (GLP-1RAs), a class of drugs widely used for diabetes and weight management, and an increased risk of NAION. This uncertainty has created a clinical dilemma, prompting further investigation into the ocular safety profile of these widely prescribed medications.

This study investigated the association between GLP-1 receptor agonist exposure and the hazard of nonarteritic anterior ischemic optic neuropathy (NAION) in a specific adult population. The researchers focused on individuals diagnosed with optic disc drusen who also had either type-2-diabetes or obesity. The primary objective was to determine if the use of GLP-1RAs, as a class, correlated with an elevated risk of developing NAION in this vulnerable group. The study design aimed to assess this association, likely through a retrospective cohort analysis, comparing outcomes in those exposed to GLP-1RAs versus unexposed or comparator groups, though specific details on cohort size, duration of follow-up, or exact GLP-1RA dosing protocols were not provided in the abstract.

In adults presenting with optic disc drusen and diagnosed with either type-2-diabetes or obesity, exposure to glucagon-like peptide-1 receptor agonists (GLP-1RAs) was found to have no statistically significant association with an increased hazard of nonarteritic anterior ischemic optic neuropathy (NAION). This finding suggests that, within the observed parameters, GLP-1RA use does not elevate the immediate risk of this specific ocular adverse event in this patient demographic. The analysis indicated a neutral relationship between the medication class and NAION incidence. However, a crucial caveat was noted: > moderate risk increases could not be excluded statistically. This implies that while a strong association was not detected, the study's power or design might not have been sufficient to definitively rule out smaller, yet clinically relevant, increases in NAION risk. No specific hazard ratios, confidence intervals, or p-values were provided in the abstract to quantify the observed non-association or the potential for moderate risk increases.